Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93Amouse model of amyotrophic lateral sclerosis

John D. Lee,
Ning Liu,
Samantha C. Levin,
Lars Ottosson,
Ulf Andersson,
Helena E. Harris and
Trent M. WoodruffEmail author View ORCID ID profile

Journal of Neuroinflammation201916:45

https://doi.org/10.1186/s12974-019-1435-2

Received: 16 November 2018
Accepted: 13 February 2019
Published: 19 February 2019

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease without effective treatment. The receptor for advanced glycation end products (RAGE) and the toll-like receptor (TLR) system are major components of the innate immune system, which have been implicated in ALS pathology. Extracellularly released high-mobility group box 1 (HMGB1) is a pleiotropic danger-associated molecular pattern (DAMP), and is an endogenous ligand for both RAGE and TLR4.

Methods

The present study examined the effect of HMGB1 inhibition on disease progression in the preclinical SOD1G93A transgenic mouse model of ALS using a potent anti-HMGB1 antibody (2G7), which targets the extracellular DAMP form of HMGB1.

Results

We found that chronic intraperitoneal dosing of the anti-HMGB1 antibody to SOD1G93A mice transiently improved hind-limb grip strength early in the disease, but did not extend survival. Anti-HMGB1 treatment also reduced tumour necrosis factor α and complement C5a receptor 1 gene expression in the spinal cord, but did not affect overall glial activation.

Conclusions

In summary, our results indicate that therapeutic targeting of an extracellular DAMP, HMGB1, improves early motor dysfunction, but overall has limited efficacy in the SOD1G93A mouse model of ALS.